Temporal and Geographic Variations in the Receipt of Colony-Stimulating Factors and Erythropoiesis-Stimulating Agents in a Large Retrospective Cohort of Older Women With Breast Cancer From 2000 to 2009

American Journal of Therapeutics
Xianglin L DuDale Hardy

Abstract

The purpose of this study was to use the most recent national data for a large cohort of patients diagnosed with breast cancer to evaluate temporal trend of receiving hematopoietic growth factors from 2000 to 2009 and to examine significant factors associated with increasing trends and geographic variations. We identified 26,130 women aged 65-89 years who were diagnosed with breast cancer and received chemotherapy in 2000-2009 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Colony-stimulating factors (CSFs) were identified if there was a claim from the following procedure codes: filgrastim, pegfilgrastim, or sargramostim. Erythropoiesis-stimulating agents (ESAs) were identified if there was a claim from the following procedure codes: epoetin or darbepoetin. Overall, 51.7% of patients with breast cancer received CSFs, which increased from 21.7% in 2000 to 63.2% in 2009. The percentage of patients receiving pegfilgrastim increased from 2.7% in 2000 to 19.5% in 2003 and then continuously to 49.7% in 2009. The overall percentage of patients receiving ESAs was 39.3%, which increased from 26.4% in 2000 to 60.8% in 2006, and then decreased significantly from 40.7% in 2007 to 12.9% in 2009. The receipt of bot...Continue Reading

References

Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G MorstynK Alton
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jun 19, 1997·The New England Journal of Medicine·L C HartmannC G Moertel
Apr 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G SwansonE T Herfindal
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H OzerUNKNOWN American Society of Clinical Oncology
Jan 4, 2001·Journal of the National Cancer Institute·R García-CarboneroL Paz-Ares
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·X Du, J S Goodwin
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L Balducci, G H Lyman
Apr 17, 2001·Current Opinion in Hematology·L BalducciG H Lyman
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Douglas RizzoUNKNOWN American Society of Clinical Oncology. American Society of Hematology
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D GreenUNKNOWN International Pegfilgrastim 749 Study Group
Dec 4, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Gary H LymanLodovico Balducci
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanJeffrey Crawford
Sep 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard I Fisher
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelLee S Schwartzberg
Nov 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinEric P Winer
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xianglin L DuShenying Fang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.